| Literature DB >> 34322832 |
Erik Lagolio1, Jacopo Demurtas2, Thomas Benzing3,4, Maria Cristina Polidori3,4, Roberto Buzzetti5, Giorgio Cortassa1, Stefania Bottone1, Laura Spadafora1, Cristina Cocino1, Lee Smith6.
Abstract
There is no univocal standardized strategy to predict outcomes and stratify risk of SARS-CoV-2 infected patients, notably in emergency departments. Our aim is to develop an accurate indicator of adverse outcomes based on a retrospective analysis of a COVID-19 database established at the Emergency Department (ED) of a North-Italian hospital during the first wave of SARS-CoV-2 infection. Laboratory, clinical, psychosocial and functional characteristics including those obtained from the Braden Scale-a standardized scale to quantify the risk of pressure sores which takes into account aspects of sensory perception, activity, mobility and nutrition-from the records of 117 consecutive patients with swab-positive COVID-19 disease admitted to the Emergency Medicine ward between March 1, 2020 and April 15, 2020 were included in the analysis. Adverse outcomes included admission to the Intensive Care Unit (ICU) and in-hospital death. Among the parameters collected, the highest cutoff sensitivity and specificity scores to best predict adverse outcomes were displayed by lactate dehydrogenase (LDH) blood value at admission > 439 U/L, Horowitz Index (P/F Ratio) < 257 and Braden score < 18. The estimation power reached 93.6%. We named the assessment BLITZ (Braden-LDH-HorowITZ). Despite the retrospective and preliminary nature of the data, a multidimensional tool to assess overall functions, not chronological age, produced the highest prediction power for poor outcomes in relation to SARS-CoV-2 infection. Further analyses are now needed to establish meaningful correlations between ventilation therapies and multidimensional frailty as assessed by ad-hoc validated and standardized tools.Entities:
Keywords: COVID-19; Emergency; Frailty; Prognostic assessment
Mesh:
Substances:
Year: 2021 PMID: 34322832 PMCID: PMC8318055 DOI: 10.1007/s11739-021-02805-w
Source DB: PubMed Journal: Intern Emerg Med ISSN: 1828-0447 Impact factor: 5.472
Characteristics of the sample
| % | Mean (DS) | Median | Min–max | ||
|---|---|---|---|---|---|
| Female | 47 | 40.1 | |||
| Male | 70 | 59.8 | |||
| Age | 73.1 (14.4) | 77 | 41–99 | ||
| Discharged | 79 | 67.5 | |||
| Deceased | 38 | 32.4 | |||
| Length of hospital stay | 14.6 (14.9) | 8 | |||
| Admitted to ICU | 17 | 14.5 |
Demographic, clinical and laboratory variables associated with outcomes
| Variables | Best cut-off | Sens (best cutoff) | Spec (best cutoff) | ||
|---|---|---|---|---|---|
| Age | 117 | > 84 | 38.0% | 80.3% | 0.220 |
| Smoke (past) | 30 | 22.2% | 47.6% | 0.106 | |
| Social distancing—R (above 1 m) | 115 | 33.3% | 77.6% | 0.192 | |
| CHD | 117 | 8.0% | 79.1% | 0.056 | |
| Overweight | 82 | 28.6% | 93.6% | 0.007 | |
| Dementia | 117 | 30.0% | 79.1% | 0.259 | |
| Number of drugs | 115 | ≥ 6 | 44.9% | 80.3% | 0.207 |
| Not 100% self-sufficient | 115 | 20.8% | 83.6% | 0.546 | |
| Confined in bed | 115 | 22.9% | 91.0% | 0.038 | |
| Fever | 117 | 78.0% | 26.9% | 0.547 | |
| Cough | 117 | 34.0% | 59.7% | 0.487 | |
| Dyspnea | 117 | 72.0% | 41.8% | 0.124 | |
| Tachypnoea | 107 | 56.3% | 76.3% | 0.001 | |
| Cyanosis | 106 | 21.3% | 96.6% | 0.004 | |
| Braden total | 101 | < 18 | 84.8% | 63.6% | 0.000 |
| PO2 | 54 | < 54.4 | 70.0% | 88.2% | 0.000 |
| HCO3 | 37 | < 23.0 | 78.6% | 78.3% | 0.010 |
| Lactate | 49 | ≥ 1.3 | 70.0% | 72.4% | 0.003 |
| P/F | 76 | < 257 | 74.3% | 70,7% | 0.000 |
| SpO2% | 102 | < 95 | 85.7% | 51.7% | 0.010 |
| PCR | 112 | ≥ 89.8 | 68.8% | 70.3% | 0.000 |
| PCT | 90 | ≥ 0.18 | 66.7% | 76.5% | 0.000 |
| Fibrinogen | 103 | < 511 | 51.2% | 68.9% | 0.182 |
| LDH | 97 | ≥ 439 | 61.0% | 87.5% | 0.000 |
| AST | 95 | ≥ 44 | 61.0% | 74.1% | 0.004 |
| Creat | 111 | ≥ 1.57 | 33.3% | 84.1% | 0.031 |
| CPK | 105 | ≥ 84 | 83.3% | 43.9% | 0.003 |
| CPAP | 117 | 58.0% | 79.1% | 0.000 |
CHD, coronary heart disease; PCR, polymerase chain reaction; PCT, procalcitonin; LDH, lactate dehydrogenase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; CPAP, continuous positive airway pressure
Composite outcome-identified variables of the BLITZ estimated by multiple logistic regression
| Source | Beta coeff | Standard error | Odds ratio | OR 95% CI lower | OR 95% CI upper | |
|---|---|---|---|---|---|---|
| Intercept | − 2192 | 0.423 | 0.316 | |||
| BRADEN < 18 | 1358 | 0.502 | 0.007 | 3.888 | 1.453 | 10.405 |
| LDH ≥ 439 | 2261 | 0.548 | < 0.0001 | 9.593 | 3.278 | 28.070 |
| P/F < 257 | 1258 | 0.480 | 0.008 | 3.517 | 1.373 | 9.010 |
Estimate of the risk of adverse outcome for the different combinations of the 3 risk factors included in BLITZ (1 = yes, 0 = no)